Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Buforin IIb in Antimicrobial and Anticancer Pharmacology; Crossing Membranes, Crossing Therapeutic Boundaries.

Created on 17 Nov 2026

Authors

Vasilis Paspaliaris, Michail Spathakis, Muhammad I Uddin, Jun Kato, George Kolios, Nikolas Dovrolis

Published in

European journal of pharmacology. Pages 179576. Nov 16, 2026. Epub Nov 16, 2026.

Abstract

Buforin IIb is a 21-residue antimicrobial peptide rationally engineered from buforin II, which itself derives from the histone H2A-derived gastric peptide buforin I. Unlike many cationic host-defence peptides that kill primarily through membrane permeabilization, buforin IIb can cross microbial and cancer-cell membranes with limited lytic disruption and engage intracellular targets, including nucleic acids and organelles. These properties support its broad antimicrobial activity and preferential cytotoxicity toward multiple malignant cell lines. This review traces the structural determinants of this activity, principally a helix-hinge-helix architecture organized around a single proline residue and examines the mechanistic evidence for ganglioside-mediated cancer-cell recognition, mitochondria- and endoplasmic-reticulum-associated apoptotic signalling, reported p53-associated responses, cell-cycle arrest, and ARF6-associated immunogenic cell death. It also examines pharmaceutical engineering strategies developed to address the peptide's principal limitations, including limited in vivo stability, incomplete cancer selectivity, and hemolytic activity at high concentrations. These strategies include matrix metalloproteinase-activatable prodrugs, BR2-based delivery systems, nanoparticle and metal bioconjugates, N-terminal lipidation, and tumour-responsive combination nanomedicines. The review synthesizes evidence from primary experimental studies describing the structural determinants, pharmacological activities, and therapeutic engineering of buforin IIb. Finally, it critically examines the major translational challenges that continue to limit its clinical development, including stability, selectivity, pharmacokinetics, and scalable manufacturing.

PMID:
43039281
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement